AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients. METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort. RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality. CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.
AIMS: To test whether the genetic variant CCR5Delta32 in the CC-chemokine receptor 5, which is known to lead to CCR5deficiency, is associated with mortality in type 2 diabetespatients. METHODS: We examined the effect of presence or absence of the CCR5Delta32 on overall and cardiovascular mortality risk in the Zwolle OutpatientDiabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetespatient cohort. RESULTS: We studied 756 patients with a mean duration of follow-up of 5.4 (+/- 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Delta32 deletion. CCR5Delta32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular mortality. CONCLUSIONS: The presence of CCR5Delta32 is associated with better survival in type 2 diabetespatients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabeticpatients.
Authors: Friso L H Muntinghe; Wayel H Abdulahad; Minke G Huitema; Jeffrey Damman; Marc A Seelen; Simon P M Lems; Bouke G Hepkema; Gerjan Navis; Johanna Westra Journal: PLoS One Date: 2012-02-13 Impact factor: 3.240
Authors: Jeremy D Gale; Steven Gilbert; Samuel Blumenthal; Tom Elliott; Pablo E Pergola; Kosalaram Goteti; Wim Scheele; Christelle Perros-Huguet Journal: Kidney Int Rep Date: 2018-08-03